Opus Genetics, Inc.: Boxer Capital Management, LLC discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Boxer Capital Management disclosed a stake exceeding 5% in Opus Genetics via a Schedule 13G filing with the SEC (accession 0001213900-26-120703). The exact share count and percentage were not specified in the headline disclosure. The move signals activist or strategic interest in the gene therapy developer. Investors will watch for further 13G/13D amendments and any engagement between Boxer and Opus management.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Boxer Capital Management, LLC, Opus Genetics, Inc.